Hyponatremia

Hyponatremia is defined as a serum sodium concentration below the reference interval, typically less than 140 mEq/L in dogs and cats, with clinical signs usually manifesting when serum sodium falls below 130 mEq/L. Sodium is the principal cation of the extracellular fluid (ECF) and the primary determinant of plasma osmolality. Hyponatremia reflects a relative excess of water to sodium, indicating either a loss of sodium or a gain of water. It is a common electrolyte disturbance in veterinary medicine, often secondary to underlying diseases such as gastrointestinal loss, renal disease, endocrine disorders, or iatrogenic fluid therapy. The clinical severity depends on the magnitude and rate of decline in serum sodium, as rapid decreases can lead to cerebral edema and neurological signs, while chronic hyponatremia may be asymptomatic due to cellular adaptation. Hyponatremia is classified based on plasma osmolality into hypertonic, isotonic, and hypotonic forms, with hypotonic hyponatremia being the most clinically relevant. Further subclassification is based on ECF volume status: hypovolemic, euvolemic, and hypervolemic hyponatremia. Accurate diagnosis and management require a thorough understanding of the underlying pathophysiology and careful correction to avoid osmotic demyelination syndrome.

The etiologies of hyponatremia are diverse and can be categorized by the underlying mechanism. Hypovolemic hyponatremia results from true sodium loss, which can be renal or extrarenal. Extrarenal causes include gastrointestinal losses (vomiting, diarrhea), third-space losses (pancreatitis, peritonitis, pleural effusion), and cutaneous losses (burns). Renal causes include diuretic use (furosemide, thiazides), osmotic diuresis (diabetes mellitus, mannitol), and salt-losing nephropathy. Euvolemic hyponatremia is typically due to water retention without significant ECF volume depletion, often associated with syndrome of inappropriate antidiuretic hormone secretion (SIADH), which can be idiopathic or secondary to pulmonary or intracranial disease, neoplasia, or drugs. Other euvolemic causes include hypothyroidism, glucocorticoid deficiency, and psychogenic polydipsia. Hypervolemic hyponatremia occurs in conditions with increased total body sodium and water, such as congestive heart failure, cirrhosis, and nephrotic syndrome, where effective circulating volume is reduced, leading to non-osmotic ADH release. Additionally, hypertonic hyponatremia can occur with hyperglycemia or mannitol administration, where the osmotic shift of water from intracellular to extracellular dilutes sodium. Isotonic hyponatremia is rare and may be seen with pseudohyponatremia due to severe hyperlipidemia or hyperproteinemia. In veterinary patients, common specific causes include hypoadrenocorticism (Addison's disease), which is a classic cause of hyponatremia with hyperkalemia, and gastrointestinal disease. Other causes include renal failure, hepatic failure, and iatrogenic fluid therapy with hypotonic fluids.

Hyponatremia is a common electrolyte disorder in dogs and cats, with reported prevalence ranging from 10% to 30% in hospitalized patients. It can occur in any breed, age, or sex, but certain conditions predispose to its development. Hypoadrenocorticism is more common in young to middle-aged female dogs, with breeds such as Standard Poodles, West Highland White Terriers, and Portuguese Water Dogs being overrepresented. Gastrointestinal disease is a frequent cause of hypovolemic hyponatremia in both dogs and cats, particularly in cases of severe vomiting or diarrhea. Chronic kidney disease is a common cause in older cats and dogs, leading to impaired renal concentrating ability and sodium loss. Congestive heart failure is more prevalent in older small-breed dogs, such as Cavalier King Charles Spaniels, and can lead to hypervolemic hyponatremia. SIADH is rare but has been reported in dogs with intracranial disease or neoplasia. There is no strong seasonal variation, but heat stress and excessive water intake may contribute to dilutional hyponatremia in exercising dogs. Overall, the prognosis and clinical impact depend on the underlying cause and the rate of sodium decline.

The pathophysiology of hyponatremia involves a disruption in the balance between sodium and water homeostasis. Sodium is the primary determinant of ECF osmolality, and its concentration is tightly regulated by thirst, ADH secretion, and renal handling. In most cases, hyponatremia results from an excess of water relative to sodium, leading to hypotonicity of the ECF. This hypotonicity causes water to shift into cells, particularly neurons, leading to cell swelling and cerebral edema. The brain adapts to chronic hyponatremia by losing intracellular solutes (osmolytes) to reduce swelling, but this adaptation makes the brain vulnerable to rapid correction, which can cause osmotic demyelination syndrome. The underlying mechanisms vary by type: hypovolemic hyponatremia involves a true sodium deficit, leading to decreased ECF volume and stimulation of ADH release via baroreceptors, which impairs water excretion. Euvolemic hyponatremia, such as SIADH, involves inappropriate ADH secretion, leading to water retention and dilution of sodium without significant volume depletion. Hypervolemic hyponatremia occurs in edematous states where there is increased total body sodium and water, but effective arterial blood volume is reduced, causing non-osmotic ADH release and water retention. In hyperglycemia, the osmotic effect of glucose draws water out of cells, diluting sodium (hypertonic hyponatremia). Pseudohyponatremia occurs when there is an artifact due to high lipid or protein levels, which reduce the aqueous fraction of plasma, but the measured sodium is falsely low. The clinical signs are primarily neurological and correlate with the severity and rapidity of the sodium decrease.

Several factors predispose animals to hyponatremia. Intrinsic factors include age (neonates and geriatrics have reduced renal concentrating ability), breed (certain breeds are predisposed to hypoadrenocorticism), and concurrent diseases such as renal, hepatic, or cardiac disease. Extrinsic factors include the use of diuretics, particularly furosemide, which can cause sodium loss. Hypotonic fluid administration (e.g., 5% dextrose in water) can cause dilutional hyponatremia, especially in patients with impaired free water excretion. Gastrointestinal losses from vomiting or diarrhea are common predisposing factors. Endocrine disorders such as hypoadrenocorticism and hypothyroidism increase susceptibility. Psychogenic polydipsia, where animals ingest excessive water, can lead to dilutional hyponatremia. Additionally, certain drugs such as thiazide diuretics, SSRIs, and chemotherapeutic agents can cause SIADH. In hospitalized patients, inadequate monitoring of fluid therapy and electrolyte status can precipitate iatrogenic hyponatremia. Understanding these risk factors is crucial for prevention and early recognition.

Clinical signs of hyponatremia are primarily neurological and depend on the severity and rate of onset. Mild hyponatremia (serum sodium 130-140 mEq/L) may be asymptomatic or cause subtle signs such as lethargy, anorexia, and mild weakness. Moderate hyponatremia (120-130 mEq/L) can lead to more pronounced signs including depression, confusion, ataxia, and muscle weakness. Severe hyponatremia (<120 mEq/L) or acute decreases can cause seizures, coma, and even death due to cerebral edema. In chronic hyponatremia, signs may be less severe due to brain adaptation. Physical examination may reveal signs of the underlying cause, such as dehydration (hypovolemic), edema or effusions (hypervolemic), or normal hydration (euvolemic). In hypoadrenocorticism, additional signs include vomiting, diarrhea, bradycardia, and weak pulse. In congestive heart failure, signs include cough, dyspnea, and exercise intolerance. Neurological examination may show altered mentation, cranial nerve deficits, and abnormal posturing. It is important to note that the rate of sodium decline is critical; a rapid drop can cause severe signs even at moderate levels, while a slow decline may be tolerated.

Differential diagnoses for hyponatremia include: 1) Hypoadrenocorticism (Addison's disease) - characterized by hyponatremia, hyperkalemia, and a low aldosterone/cortisol response to ACTH stimulation. 2) Gastrointestinal disease (e.g., severe vomiting/diarrhea) - history and clinical signs, with dehydration and metabolic alkalosis or acidosis. 3) Chronic kidney disease - azotemia, isosthenuria, and renal ultrasonographic changes. 4) Congestive heart failure - history, physical exam (murmur, crackles), thoracic radiography showing cardiomegaly and pulmonary edema. 5) Hepatic failure - icterus, hypoalbuminemia, elevated liver enzymes, and ascites. 6) SIADH - euvolemic hyponatremia with concentrated urine and normal renal, adrenal, and thyroid function. 7) Psychogenic polydipsia - history of excessive water intake, dilute urine, and normal osmoregulation. 8) Hyperglycemia (diabetes mellitus) - hyperglycemia, glucosuria, and ketonuria. 9) Pseudohyponatremia - hyperlipidemia or hyperproteinemia, with normal measured osmolality. 10) Diuretic use - history of furosemide or thiazide administration. Each differential is ruled in or out based on history, physical exam, and specific diagnostic tests such as ACTH stimulation, serum biochemistry, urinalysis, and imaging.

The diagnostic approach to hyponatremia should be systematic. Step 1: Confirm hyponatremia with serum biochemistry and assess plasma osmolality (calculated or measured). If osmolality is low, proceed; if normal, consider pseudohyponatremia; if high, consider hyperglycemia or mannitol. Step 2: Assess ECF volume status via physical examination (skin turgor, mucous membranes, heart rate, blood pressure, jugular venous distension, presence of edema or effusions). Step 3: Classify into hypovolemic, euvolemic, or hypervolemic. Step 4: For hypovolemic, evaluate for extrarenal losses (history of vomiting/diarrhea) or renal losses (urine sodium concentration >20 mEq/L suggests renal loss). Step 5: For euvolemic, assess urine osmolality and urine sodium; if urine osmolality is inappropriately high (>100 mOsm/kg) and urine sodium >40 mEq/L, consider SIADH; also rule out hypothyroidism and glucocorticoid deficiency. Step 6: For hypervolemic, evaluate cardiac, hepatic, and renal function via thoracic radiography, echocardiography, abdominal ultrasound, and serum biochemistry. Step 7: Perform baseline diagnostics including CBC, serum biochemistry (including electrolytes, glucose, BUN, creatinine, albumin, total protein, liver enzymes), urinalysis, and blood pressure measurement. Step 8: If hypoadrenocorticism is suspected, perform ACTH stimulation test. Step 9: Consider additional tests such as thyroid hormone levels, cortisol, and imaging (abdominal ultrasound, thoracic radiography, echocardiography) based on clinical suspicion. Step 10: In refractory cases, measure plasma osmolality and urine osmolality to confirm SIADH. This algorithm ensures a thorough evaluation and appropriate management.

Laboratory findings in hyponatremia include: Serum sodium <140 mEq/L (dogs and cats). Other electrolytes may be abnormal: hyperkalemia is common in hypoadrenocorticism; hypochloremia often accompanies hyponatremia. Blood gas analysis may reveal metabolic acidosis (e.g., diarrhea, renal failure) or alkalosis (e.g., vomiting). Hematology may show hemoconcentration (increased PCV, total protein) in hypovolemic states, or anemia in chronic disease. Serum biochemistry may reveal azotemia (renal disease), hypoalbuminemia (hepatic or renal loss), hyperglycemia (diabetes mellitus), or elevated liver enzymes. Urinalysis: urine specific gravity (USG) is low (<1.030) in psychogenic polydipsia or SIADH, but may be high in hypovolemic states. Urine sodium concentration can help differentiate renal vs. extrarenal losses: >20 mEq/L suggests renal sodium loss, <10 mEq/L suggests extrarenal loss. In SIADH, urine osmolality is inappropriately high (>100 mOsm/kg) relative to plasma. Endocrine testing: ACTH stimulation test shows low baseline cortisol and inadequate response in hypoadrenocorticism. Thyroid hormone levels (total T4, free T4) may be low in hypothyroidism. Biomarkers such as NT-proBNP may be elevated in heart failure. In pseudohyponatremia, serum triglycerides or total protein are elevated, and measured osmolality is normal.

Imaging findings depend on the underlying cause. Thoracic radiography: In congestive heart failure, there may be cardiomegaly, pulmonary edema, and pleural effusion. In pulmonary disease (e.g., neoplasia, pneumonia) that may cause SIADH, there may be mass lesions or infiltrates. Abdominal ultrasonography: In hypoadrenocorticism, the adrenal glands may be small (atrophic) or normal; in chronic kidney disease, kidneys may be small and irregular with increased echogenicity; in hepatic disease, there may be hepatomegaly, ascites, or microhepatica. Echocardiography is essential for diagnosing cardiac disease, revealing chamber enlargement, valvular lesions, or reduced contractility. Computed tomography (CT) or magnetic resonance imaging (MRI) of the brain may be indicated if intracranial disease is suspected as a cause of SIADH. In cases of psychogenic polydipsia, imaging is typically unremarkable. Imaging is not directly diagnostic for hyponatremia but is crucial for identifying the underlying etiology.

Cytology and histopathology are not typically used for the diagnosis of hyponatremia itself, but they are valuable in identifying underlying causes. For example, in cases of suspected neoplasia causing SIADH, fine-needle aspiration (FNA) of a mass may reveal malignant cells. Histopathology of adrenal glands in hypoadrenocorticism may show lymphocytic infiltration or atrophy. In renal disease, renal biopsy may show glomerulonephritis, interstitial nephritis, or amyloidosis. In hepatic disease, liver biopsy may reveal cirrhosis, hepatitis, or neoplasia. These findings help confirm the etiology and guide treatment. However, in most cases of hyponatremia, the diagnosis is made through clinical and laboratory evaluation, and invasive procedures are reserved for specific indications.

Treatment of hyponatremia depends on the underlying cause, severity, and chronicity. The primary goals are to correct the sodium imbalance safely and treat the underlying disease. For hypovolemic hyponatremia, fluid resuscitation with isotonic crystalloids (e.g., 0.9% NaCl) is indicated to restore ECF volume. The rate of correction should be cautious: in chronic hyponatremia, the serum sodium should be increased by no more than 8-10 mEq/L per 24 hours to avoid osmotic demyelination syndrome. In acute severe hyponatremia with neurological signs, hypertonic saline (3% NaCl) may be used at a rate of 1-2 mL/kg over 10-15 minutes, followed by slower correction. For euvolemic hyponatremia due to SIADH, fluid restriction is the mainstay, along with treatment of the underlying cause. In hypervolemic hyponatremia, sodium and water restriction, along with diuretics (e.g., furosemide), are used. Specific treatments: For hypoadrenocorticism, replace glucocorticoids (e.g., prednisone 0.2-0.5 mg/kg/day) and mineralocorticoids (e.g., fludrocortisone 0.01-0.02 mg/kg/day or desoxycorticosterone pivalate 2.2 mg/kg IM q25d). For hypothyroidism, levothyroxine 0.02 mg/kg PO q12h. For heart failure, use diuretics, ACE inhibitors, and pimobendan. For renal disease, manage with renal diet, phosphate binders, and erythropoietin if anemic. In all cases, monitor serum sodium frequently (every 4-6 hours during correction) and adjust therapy accordingly.

The prognosis for hyponatremia depends on the underlying cause, severity, and rapidity of correction. In cases of mild to moderate hyponatremia due to reversible causes (e.g., gastrointestinal losses), the prognosis is good with appropriate fluid therapy and treatment of the primary disease. Severe hyponatremia (<120 mEq/L) carries a guarded prognosis, especially if neurological signs are present. The risk of osmotic demyelination syndrome is significant if correction is too rapid, leading to permanent neurological deficits or death. In hypoadrenocorticism, the prognosis is excellent with lifelong hormone replacement. In chronic diseases such as renal failure or heart failure, the prognosis is variable and depends on the stage and response to treatment. Overall, early recognition and careful management improve outcomes. Mortality rates in hospitalized patients with hyponatremia have been reported to be higher than those without, but this is often due to the underlying disease.

Follow-up care for hyponatremia includes serial monitoring of serum sodium, especially during the correction phase. Initially, serum sodium should be checked every 4-6 hours until stable, then daily until discharge. After discharge, recheck serum sodium and electrolytes weekly for the first month, then monthly or as needed. For patients with chronic conditions (e.g., hypoadrenocorticism, heart failure), regular monitoring of electrolytes, renal function, and clinical status is essential. Adjust medications based on follow-up results. For example, in hypoadrenocorticism, fludrocortisone dose may need adjustment based on electrolytes. In heart failure, monitor body weight, respiratory rate, and renal function. In SIADH, fluid restriction should be continued and sodium monitored. Long-term management includes dietary modifications (e.g., sodium restriction in hypervolemic states, adequate sodium in hypovolemic states) and owner education on recognizing signs of recurrence.

Pearls: 1) Always assess volume status before initiating treatment; hypovolemic patients need isotonic fluids, while euvolemic/hypervolemic patients may need fluid restriction. 2) In chronic hyponatremia, correct sodium slowly (≤8-10 mEq/L per 24 hours) to prevent osmotic demyelination. 3) In hypoadrenocorticism, hyponatremia is often accompanied by hyperkalemia; treat with saline and glucocorticoids. 4) Use calculated osmolality (2(Na) + glucose/18 + BUN/2.8) to differentiate true hyponatremia from pseudohyponatremia. 5) In SIADH, urine osmolality is inappropriately high (>100 mOsm/kg) and urine sodium >40 mEq/L. Pitfalls: 1) Rapid correction of chronic hyponatremia can cause osmotic demyelination syndrome, leading to quadriparesis and coma. 2) Using hypotonic fluids (e.g., 0.45% NaCl, 5% dextrose) in hypovolemic patients can worsen hyponatremia. 3) Overlooking hypoadrenocorticism in any sick patient with hyponatremia and hyperkalemia. 4) Failing to monitor serum sodium frequently during correction. 5) Misinterpreting pseudohyponatremia as true hyponatremia, leading to unnecessary treatment.

Drug protocols for hyponatremia are directed at the underlying cause. For hypoadrenocorticism: Prednisone (0.2-0.5 mg/kg/day PO, divided q12h) and fludrocortisone acetate (0.01-0.02 mg/kg/day PO, divided q12h) or desoxycorticosterone pivalate (DOCP) (2.2 mg/kg IM or SC q25d). For acute adrenal crisis: IV fluid therapy with 0.9% NaCl, dexamethasone sodium phosphate (0.1-0.2 mg/kg IV) or prednisolone sodium succinate (1-2 mg/kg IV), and DOCP (2.2 mg/kg IM) if mineralocorticoid replacement is needed. For SIADH: Fluid restriction (60-80% of maintenance), and if severe, hypertonic saline (3% NaCl) at 1-2 mL/kg IV over 10-15 minutes, followed by 0.5-1 mL/kg/hr until clinical signs resolve. For heart failure: Furosemide (1-4 mg/kg IV or IM q8-12h, then 1-2 mg/kg PO q12h), enalapril (0.5 mg/kg PO q12h), and pimobendan (0.25 mg/kg PO q12h). For chronic kidney disease: Manage with renal diet, phosphate binders (e.g., aluminum hydroxide 30-100 mg/kg/day PO), and erythropoietin (100 U/kg SC three times weekly) if anemic. For hypothyroidism: Levothyroxine (0.02 mg/kg PO q12h). For psychogenic polydipsia: Behavioral modification and water restriction. Always adjust dosages based on renal/hepatic function and monitor for drug interactions.

Evidence-based literature on hyponatremia in veterinary medicine is limited but growing. Key studies include: 1) A retrospective study by DiBartola et al. (1980) described the clinical and clinicopathologic findings in dogs with hypoadrenocorticism, highlighting hyponatremia and hyperkalemia as classic features. 2) A study by Seth et al. (2011) evaluated the prevalence and causes of hyponatremia in hospitalized dogs, finding that gastrointestinal disease and renal disease were common causes. 3) A consensus statement from the ACVIM on the diagnosis and treatment of hypoadrenocorticism (2016) provides guidelines for management. 4) Research on SIADH in dogs is limited to case reports, but a study by Nakamura et al. (2017) described SIADH in a dog with intracranial disease. 5) The use of hypertonic saline for acute hyponatremia has been extrapolated from human medicine, with a study by Sterns et al. (1994) emphasizing the risk of osmotic demyelination with rapid correction. 6) A study by Rishniw et al. (2012) evaluated the accuracy of calculated osmolality in dogs and cats, supporting its use in clinical practice. 7) The IRIS guidelines for chronic kidney disease provide recommendations for managing electrolyte imbalances, including hyponatremia. Overall, evidence supports a cautious approach to correction and treatment of the underlying cause.